欢迎访问浙江中西医结合杂志   今天是   加入收藏   |   设为首页
黄崇青,虞冠锋,黄景勇,麻朋艳,万丽,范良好.雷珠单抗竞争结合血管内皮生长因子A抑制裸鼠皮下血管瘤细胞生长[J].浙江中西医结合杂志,2017,27(9):
雷珠单抗竞争结合血管内皮生长因子A抑制裸鼠皮下血管瘤细胞生长
Inhibition of vascular endothelial growth factor A by Ranibizumab in the subcutaneous hemangiomas in nude mice
投稿时间:2017-02-22  修订日期:2017-05-16
DOI:
中文关键词:  血管瘤  血管内皮生长因子A  雷珠单抗  平阳霉素
英文关键词:Hemangioma  VEGF-A  Ranibizumab  Pingyangmycin
基金项目:温州市公益性社会发展科技项目(Y20160407)
作者单位E-mail
黄崇青 温州医科大学附属第一医院 christopherhuang@qq.com 
虞冠锋 温州医科大学附属第一医院  
黄景勇 温州医科大学附属第一医院  
麻朋艳 温州医科大学附属第一医院  
万丽 温州医科大学附属第一医院  
范良好 温州医科大学附属第一医院  
摘要点击次数: 46
全文下载次数: 
中文摘要:
      目的:探索雷珠单抗(Ranibizumab)竞争结合血管内皮生长因子A(VEGF-A)抑制裸鼠皮下结缔组织血管瘤的相对疗效及副作用。方法:血管瘤细胞注射法成功建立动物实验模型,分为A组:无药物治疗的基础对照组;B组:注射 0.25 mg/cm3的雷珠单抗实验组;C组:注射0.5 mg/cm3的雷珠单抗实验组;D组:注射0.75 mg/cm3的雷珠单抗实验组;E组:注射1 mg/cm3的平阳霉素药物对照组。结果:9-12天血管瘤体积增长最快,因此这段时间是药物治疗血管瘤最好的窗口期。各药物治疗2周后,血管瘤体积均有减小(A组171.76±52.46mm3,B组70.85±8.73mm3,C组69.84±16.33mm3,D组41.83±18.65mm3,E组61.52±8.12mm3,p<0.01),且0.75mg/cm3的雷珠单抗治疗组疗效明显优于平阳霉素治疗组,并且效果最为明显。不同浓度雷珠单抗治疗组及平阳霉素治疗组裸鼠血管瘤组织中CD34和Ki67的蛋白表达明显下降(p<0.01),且雷珠单抗浓度越高,下降越明显,0.75 mg/cm3的雷珠单抗治疗组和平阳霉素治疗组效果最明显。各药物治疗后,裸鼠肺组织受到不同程度的损伤,其他组织无明显变化,但0.75 mg/cm3的雷珠单抗治疗组对于肺组织的损伤要轻于平阳霉素。结论:利用细胞注射法建立裸鼠皮下血管瘤模型的方法是切实可行与成熟的。对比平阳霉素,雷珠单抗治疗皮下结缔组织血管瘤病变,抑制异常增生血管瘤组织的作用是显著的,且均不影响对于生命相关的循环、消化及泌尿系统,而对于肺组织的损伤要轻于平阳霉素。
英文摘要:
      Objective: To explore the relative efficacy and side effects of Ranibizumab competitive combined with vascular endothelial growth factor A (VEGF-A) in inhibiting subcutaneous hemangioma in nude mice. Methods: The animal model was established by injecting hemagioma cells to subcutaneous tissue of nude mice. The nude mice were divided into 5 groups. Group A: control group, without drug therapy. Group B: group of injection with 0.25 mg / cm3 Ranibizumab. Group C: group of injection with 0.5 mg / cm3 Ranibizumab. Group D: injection of 0.75 mg / cm3 Ranibizumab. Group E: drug control group, injection of 1 mg / cm3 Pingyangmycin. Results: Tumor grew the fastest during 9 to 12 days. So, this time was the best period for drug treatment of tumors. 2 weeks after treatment by drugs, the tumor volume was reduced (Group A 171.76±52.46mm3,Group B 70.85±8.73mm3,Group C 69.84±16.33mm3,Group D 41.83±18.65mm3,Group E 61.52±8.12mm3,p<0.01), and 0.75mg / cm3 Ranibizumab treatment group was significantly better than the treatment of Pingyangmycin treatment group, and the effect is most obvious. The expression of CD34 and Ki67 protein in the tumor tissue of nude mice treated with different concentrations of Ranibizumab and Pingyangmycin was significantly decreased (p<0.01), and the lower concentration of Ranibizumab, the more obvious. 0.75 mg / cm3 Ranibizumab treatment group and Pingyangmycin treatment group were of the most obvious effect. After treatment, the lung tissue of nude mice was damaged in different degrees, and no changes were observed in other tissues. However, of 0.75 mg / cm3 Ranibizumab was lesser than that of Pingyangmycin. Conclusion: The method of using cell injection to establish model of subcutaneous hemangioma in nude mice is feasible and mature. Compared with Pingyangmycin and Ranibizumab in the treatment of subcutaneous connective tissue hemangioma lesions, the role of abnormal proliferation of hemangioma tissue by Ranibizumab is significant, and do not affect the circulation, digestion and urinary system. In addition, Injury of lung tissue was lesser than Pingyangmycin.
查看全文  查看/发表评论  下载PDF阅读器
关闭